The effects of denosumab compared with oral bisphosphonates (BP) in patients with RA complicated with osteoporosis on the progression of structural damage, BMD and disease activity.
Not Applicable
- Conditions
- rheumatoid arthritis
- Registration Number
- JPRN-UMIN000014737
- Lead Sponsor
- Yokohama City University Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 286
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Use of a biologics agent for RA within 8 weeks before trial (2) Use of JAK inhibitor (3) Gulcocorticoid dose >10mg/day (prednisone or equivalent) (4) Patients whom the doctor judged unsuitable for participation from medical reason.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The change in mTSS from baseline to 52 weeks
- Secondary Outcome Measures
Name Time Method The changes from baseline to 52 weeks in DAS28,SDAI,CDAI and BMD